LataMed AI Corp. (OTC: LMEDD), a development-stage digital health and artificial intelligence technology company, announced today that its previously announced 5-for-1 forward stock split has become effective at the opening of trading following publication of the corporate action on the FINRA Daily List dated July 14, 2026. The forward stock split is a significant corporate milestone for the company, which is focused on building telehealth infrastructure and AI-enabled healthcare solutions for emerging markets, with an initial regional focus on Latin America.
In connection with the forward stock split, the company's common stock will begin trading today under the temporary trading symbol LMEDD. The temporary "D" designation is a standard FINRA identifier used in connection with certain corporate actions and is expected to remain in place for approximately twenty (20) business days, after which the trading symbol is expected to revert to LMED. The forward stock split has also been implemented in conjunction with the company's mandatory share exchange and new CUSIP number, 21116R404. As a result, the company's prior CUSIP number, 21116R305, is being suspended effective upon market effectiveness of the forward stock split.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: "Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms." The company's strategy centers on developing technology platforms designed to support healthcare access, patient engagement, provider coordination, emergency medical response, pharmacy integration, insurance accessibility, payment solutions, and data-driven healthcare operations.
The company reminded shareholders that those holding shares through brokerage accounts or in electronic book-entry form generally are not required to take any action. Brokerage firms, custodians, and other market participants are expected to process the corporate action automatically through the normal securities settlement process. Shareholders holding physical stock certificates are not required to immediately surrender their certificates. However, when physical certificates are presented to the company's transfer agent for transfer, sale, or exchange, they will be processed in accordance with the mandatory exchange procedures then in effect and exchanged for the appropriate number of post-split shares under the new CUSIP.
The forward stock split is expected to impact the company's capital structure and may affect the liquidity and trading price of its common stock. For investors, this corporate action could signal the company's intent to improve marketability and potentially attract a broader investor base as it advances its AI-driven healthcare solutions. LataMed AI's focus on artificial intelligence platforms such as CardioAI, PulmoAI, and NeuroAI positions it within the growing digital health sector, where AI is increasingly used to enhance diagnostic capabilities and healthcare delivery in underserved regions.
The company is a development-stage entity, and its securities involve a high degree of risk. Prospective investors are urged to carefully review all risk factors and disclosures contained in the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov before making any investment decision. For additional information about the company and its platforms, visit https://latamed.ai.
